A Phase 1, Open-Label Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of RG-012 for Injection in Subjects With Alport Syndrome
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2018
At a glance
- Drugs RG 012 (Primary)
- Indications Hereditary nephritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Regulus Therapeutics
- 07 Nov 2017 Status changed from planning to recruiting, according to a Regulus Therapeutics media release.
- 12 May 2017 New trial record
- 04 May 2017 According to a Regulus Therapeutics media release, the company has selected dose for this trial which is expected to commence mid-2017. Data is anticipated by year-end 2017.